<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034355</url>
  </required_header>
  <id_info>
    <org_study_id>PP06489</org_study_id>
    <secondary_id>2017-004707-43</secondary_id>
    <nct_id>NCT04034355</nct_id>
  </id_info>
  <brief_title>Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer</brief_title>
  <acronym>POLAR-A</acronym>
  <official_title>A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in the Adjuvant Treatment of Patients With Stage III or High-risk Stage II Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PledPharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Solasia Pharma K.K.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PledPharma AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate PledOx for prevention of chronic chemotherapy induced peripheral
      neuropathy induced by oxaliplatin in patients with Stage III or high-risk Stage II colorectal
      cancer (CRC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, double-blind, placebo-controlled study with PledOx for
      prevention of chronic CIPN induced by oxaliplatin in patients with Stage III or high-risk
      Stage II colorectal cancer (CRC).

      Patients with CRC, who are indicated for adjuvant modified FOLFOX6 (mFOLFOX6) chemotherapy
      for up to 6 months, will be randomized in a 1:1 ratio to 1 of 2 treatment arms:

        -  Arm A: PledOx (5 µmol/kg) + mFOLFOX6 chemotherapy

        -  Arm B: Placebo + mFOLFOX6 chemotherapy

      The investigational medicinal product (IMP; i.e. PledOx or placebo) will be administered by
      an intravenous (i.v.) infusion on the first day of each chemotherapy cycle. IMP will not be
      administered if mFOLFOX6 is not given to the patient.

      If a patient discontinues oxaliplatin, treatment with 5-FU/folinate and IMP may be continued.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with colorectal cancer (CRC), who are indicated for adjuvant modified FOLFOX6 (mFOLFOX6) chemotherapy for up to 6 months, will be randomized in a 1:1 ratio to 1 of 2 treatment arms:
Arm A: PledOx (5 µmol/kg) + mFOLFOX6 chemotherapy
Arm B: Placebo + mFOLFOX6 chemotherapy</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To compare PledOx versus Placebo with respect to the proportion of patients with moderate or severe chronic chemotherapy induced peripheral neuropathy</measure>
    <time_frame>9 months</time_frame>
    <description>Proportion of patients (with moderate or severe chronic chemotherapy induced peripheral neuropathy) scoring 3 or 4 in at least 1 of the first 4 items of the FACT/GOG-NTX-13 (i.e., FACT/GOG-NTX-4), targeting numbness, tingling or discomfort in hands and/or feet, 9 months after the first dose of investigational medicinal product (IMP; i.e. PledOx or placebo administered on Day 1, Cycle 1 of mFOLFOX6 chemotherapy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with mild, moderate or severe chronic chemotherapy induced peripheral neuropathy</measure>
    <time_frame>9 months</time_frame>
    <description>Proportion of patients (with mild, moderate or severe chronic chemotherapy induced peripheral neuropathy) scoring 2, 3, or 4, in at least 1 of the first 4 items of the FACT/GOG-NTX-13 (i.e. FACT/GOG-NTX-4), targeting numbness, tingling or discomfort in hands and/or feet, 9 months after the first dose of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity to touching cold items</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mean change from baseline in sensitivity to touching cold items on Day 2, Cycle 4 (cycle is 14 days) of mFOLFOX6 chemotherapy, as assessed by the Cold Sensitivity questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of oxaliplatin during chemotherapy</measure>
    <time_frame>9 months</time_frame>
    <description>Mean cumulative dose of oxaliplatin administered per patient during mFOLFOX6 chemotherapy, 9 months after the first dose of Investigational Medicinal Product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vibration sensitivity on the lateral malleolus</measure>
    <time_frame>9 months</time_frame>
    <description>Mean change from baseline in vibration sense, on the lateral malleolus (left and right), using a graduated tuning fork, at 9 months after the first dose of Investigational Medicinal Product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst pain in hands or feet</measure>
    <time_frame>9 months</time_frame>
    <description>Mean change from baseline in worst pain in hands or feet in the past week, using a numerical rating scale (Numeric Rating Scale; Scale range of 0-10;0 = no pain, 10= pain as bad as you can imagine), at 9 months after the first dose of Investigational Medicinal Product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional impairment (in the non-dominant hand)</measure>
    <time_frame>9 months</time_frame>
    <description>Mean change from baseline in the time to complete the grooved Pegboard with the non-dominant hand, at 9 months after the first dose of Investigational Medicinal Product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained efficacy on prevention of chemotherapy induced peripheral neuropathy during long-term follow-up</measure>
    <time_frame>12, 18, 24 months</time_frame>
    <description>Proportion of patients scoring 3 or 4 in at least 1 of the first 4 items of the FACT/GOG-NTX-13 (i.e. FACT/GOG-NTX-4), targeting numbness, tingling or discomfort in hands and/or feet, 12, 18, and 24 months after the first dose of Investigational Medicinal Product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Disease free survival at 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of PledOx as assessed by Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>The occurrence of an AE may come to the attention of study personnel during study visits and interviews of a study recipient presenting for medical care, or upon review by a study monitor who is scrutinizing relevant source data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of PledOx as assessed by laboratory variables</measure>
    <time_frame>24 months</time_frame>
    <description>Blood samples for laboratory evaluation will be collected according to the Schedule of Assessments.
For each value outside the normal ranges, the Investigator should mark the value as &quot;Clinically Significant&quot; (CS) or &quot;Not Clinically Significant&quot; (NCS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of PledOx as assessed by vital signs</measure>
    <time_frame>24 months</time_frame>
    <description>Any abnormal/pathological findings should be recorded and judged as CS or NCS by the Investigator. Any clinically significant abnormalities should be recorded as medical history if detected at screening or baseline, or as AEs if detected after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of PledOx as assessed by Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>The occurrence of an AE may come to the attention of study personnel during study visits and interviews of a study recipient presenting for medical care, or upon review by a study monitor who is scrutinizing relevant source data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of PledOx as assessed by laboratory variables</measure>
    <time_frame>24 months</time_frame>
    <description>Blood samples for laboratory evaluation will be collected according to the Schedule of Assessments.
For each value outside the normal ranges, the Investigator should mark the value as &quot;Clinically Significant&quot; (CS) or &quot;Not Clinically Significant&quot; (NCS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of PledOx as assessed by vital signs</measure>
    <time_frame>24 months</time_frame>
    <description>Any abnormal/pathological findings should be recorded and judged as CS or NCS by the Investigator. Any clinically significant abnormalities should be recorded as medical history if detected at screening or baseline, or as AEs if detected after the start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>PledOx (5 µmol/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calmangafodipir 5 µmol/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride in 20 mL vials</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calmangafodipir (5 µmol/kg)</intervention_name>
    <description>PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a bright yellow clear solution in 20 mL colorless, single dose, glass vials.</description>
    <arm_group_label>PledOx (5 µmol/kg)</arm_group_label>
    <other_name>PledOx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a bright yellow clear solution in 20 mL colorless, single dose, glass vials.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent form before any study related assessments and willing to
             follow all study procedures.

          2. Male or female aged ≥18 years.

          3. Pathologically confirmed adenocarcinoma of the colon or rectum including: Stage III
             carcinoma (any T N1,2 M0) or Stage II carcinoma (T3,4 N0 M0).

          4. The patient has undergone curative (R0) surgical resection performed within 12 weeks
             prior to randomization

          5. The patient has a postsurgical carcinoembryonic antigen (CEA) level ≤1.5 x upper limit
             of normal (ULN, in current smokers, CEA level ≤2.0 x ULN is allowed).

          6. No prior anti-cancer therapy for CRC except radiotherapy or concomitant
             chemo-radiotherapy using a fluoropyrimidine alone for locoregional rectal cancer.

          7. Patient indicated for up to 6 months of oxaliplatin-based chemotherapy and without
             pathological findings of a neurologic exam performed prior to oxaliplatin treatment
             according to local practice.

          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          9. Adequate hematological parameters: hemoglobin ≥100 g/L, absolute neutrophil count ≥1.5
             x 109 /L, platelets ≥100 x 109 /L.

         10. Adequate renal function: creatinine clearance &gt;50 cc/min using the Cockcroft and Gault
             formula or measured.

         11. Adequate hepatic function: total bilirubin ≤1.5 x ULN (except in the case of known
             Gilbert's syndrome); aspartate aminotransferase (AST) and alanine aminotransferase
             (ALT) ≤3 x ULN.

         12. Baseline blood manganese (Mn) level &lt;2.0 x ULN.

         13. For patients with a history of diabetes mellitus, HbA1c ≤7%.

         14. Negative pregnancy test for women of child-bearing potential (WOCBP).

         15. For men and WOCBP, use of adequate contraception (oral contraceptives, intrauterine
             device or surgically sterile) while on study drug and for at least 6 months after
             completion of study therapy.

        Exclusion Criteria:

          1. Any evidence of metastatic disease.

          2. Any unresolved toxicity by National Cancer Institute-Common Terminology Criteria for
             Adverse Events Version (NCI-CTCAE) v.4.03 &gt;Grade 1 from previous anti-cancer therapy
             (including radiotherapy), except alopecia.

          3. Any grade of neuropathy from any cause.

          4. Any evidence of severe or uncontrolled systemic diseases (e.g., unstable or
             uncompensated respiratory, cardiac, unresolved bowel obstruction, hepatic or renal
             disease).

          5. Chronic infection or uncontrolled serious illness causing immunodeficiency. Patients
             with known history of chronic hepatitis B can be enrolled if they are asymptomatic and
             an acute and active HBV infection can be excluded.

          6. Any history of seizures.

          7. A surgical incision that is not healed.

          8. Known hypersensitivity to any of the components of mFOLFOX6 and, if applicable,
             therapies to be used in conjunction with the chemotherapy regimen or any of the
             excipients of these products.

          9. History of other malignancies (except for adequately treated basal or squamous cell
             carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease
             free for that other malignancy for at least 2 years.

         10. Known dihydropyrimidine dehydrogenase deficiency.

         11. Pre-existing neurodegenerative disease (e.g., Parkinson's, Alzheimer's, Huntington's)
             or neuromuscular disorder (e.g., multiple sclerosis, amyotrophic lateral sclerosis,
             polio, hereditary neuromuscular disease).

         12. Major psychiatric disorder (major depression, psychosis), alcohol and/or drug abuse.

         13. Patients with a history of second or third degree atrioventricular block or a family
             heredity.

         14. A history of a genetic or familial neuropathy.

         15. Treatment with any investigational drug within 30 days prior to randomization.

         16. Pregnancy, lactation or reluctance to using contraception.

         17. Any other condition that, in the opinion of the Investigator, places the patient at
             undue risk.

         18. Previous exposure to mangafodipir or calmangafodipir.

         19. Welders, mine workers or other workers in occupations (current or past) where high Mn
             exposure is likely.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Carlsson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenuis Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda GI Clinical Research Center</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Maarten</name>
      <address>
        <city>Mechelen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur - Site Godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Benesov</name>
      <address>
        <city>Benesov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Horovice</name>
      <address>
        <city>Horovice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Pleši</name>
      <address>
        <city>Nová Ves pod Plesi</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague 2</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologická Klinika 1. Lf Uk A Tn</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur-Lanroze</name>
      <address>
        <city>Brest Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental de Vendée - Unité de recherche clinique</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot - HCL</name>
      <address>
        <city>LYON Cedex 03</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté Site du Mittan</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice L'Archet 2</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste Anne</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatolgisch-onkologische Praxis Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkodok GmbH / Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Gütersloh</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Neuperlach</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Irst</name>
      <address>
        <city>Meldola - FC</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli infermi</name>
      <address>
        <city>Ponderano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS azienda Ospedaliera S Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Hospital</name>
      <address>
        <city>Toyoake</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Granvia de L´Hospitalet 199-203</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'hebron university hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.G.U.Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quironsalud Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KMUH: Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Essex Hospital Services NHS Trust - Broomfield Hospital</name>
      <address>
        <city>Chelmsford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tyneside General Hospital</name>
      <address>
        <city>North Shields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centr</name>
      <address>
        <city>Northwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital (Surrey)</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>peripheral neuropathy</keyword>
  <keyword>neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

